Back to top
more

Novo Nordisk (NVO)

(Delayed Data from NYSE)

$48.19 USD

48.19
34,745,445

+1.12 (2.38%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $48.34 +0.15 (0.31%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (96 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Lilly Jardiance Family Diabetes Drugs' Label to be Updated

by Zacks Equity Research

Eli Lilly & Company (LLY) recently announced that the FDA has approved the inclusion of data from the EMPA-REG OUTCOME study on the labels of three type 2 diabetes medicines belonging to the Jardiance family ??? Synjardy, Synjardy XR and Glyxambi.

    Indradip Ghosh headshot

    New Strong Sell Stocks for December 27th

    by Indradip Ghosh

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

      Zacks Equity Research

      Lilly Stock Surges on Robust 2017 View; Launches Basaglar

      by Zacks Equity Research

      Eli Lilly and Company (LLY) issued a better-than-expected financial guidance for 2017, alleviating investor concern to a large extent.

        Zacks Equity Research

        Eli Lilly (LLY) to Offer Discount on Insulin from January

        by Zacks Equity Research

        Eli Lilly (LLY) announced that the company will offer access to its insulin products at discounted prices, starting Jan 2017.

          Zacks Equity Research

          Lilly (LLY) Gets FDA Nod for Once-Daily Version of Synjardy

          by Zacks Equity Research

          Eli Lilly and Company (LLY) announced the FDA approval of an extended-release formulation of its type II diabetes prescription drug Synjardy.

            Arpita Dutt headshot

            Should Biotech Investors Worry About Donald Trump?

            by Arpita Dutt

            It looks like biotech investors may have heaved a sigh of relief a bit too early when Presidential election results were announced last month.

              Zacks Equity Research

              Lilly: Jardiance Label to Add Cardiovascular Indication

              by Zacks Equity Research

              Eli Lilly & Company (LLY) recently announced that the FDA has approved the inclusion of cardiovascular (CV) risk reduction data from the EMPA-REG OUTCOME study on its type II diabetes drug Jardiance's (SGLT-2 inhibitor) label.

                Zacks Equity Research

                Novo Nordisk Files Regulatory Application for Semaglutide

                by Zacks Equity Research

                Novo Nordisk (NVO) submitted regulatory application for semaglutide in both the U.S. and the EU for the treatment of adults with type II diabetes.

                  Zacks Equity Research

                  Novo Nordisk's Tresiba Shows Safe Cardiovascular Profile

                  by Zacks Equity Research

                  Novo Nordisk (NVO) announced headline results from the DEVOTE study that confirmed the cardiovascular safety of Tresiba, in comparison to Sanofi???s (SNY) Lantus.

                    Arpita Dutt headshot

                    Pharma Industry Stock Outlook - March 2016

                    by Arpita Dutt

                    Looking at consensus earnings expectations, the Medical sector, which had performed well in 2015, is expected to see earnings growth of 0.7% and revenue growth of 7.7% in Q1.

                      Arpita Dutt headshot

                      Pharma Industry Stock Outlook - March 2016

                      by Arpita Dutt

                      Looking at consensus earnings expectations, the Medical sector, which had performed well in 2015, is expected to see earnings growth of 0.7% and revenue growth of 7.7% in Q1.